7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Yang X et al. | Effects of TGF-β1 on OPG/RANKL expression of cementoblasts and osteoblasts are similar without stress but different with mechanical compressive stress. | 2015 | ScientificWorldJournal | pmid:25685846 |
Zhang Q et al. | Local gene transfer of OPG prevents joint damage and disease progression in collagen-induced arthritis. | 2013 | ScientificWorldJournal | pmid:24222748 |
Teitelbaum SL | Bone resorption by osteoclasts. | 2000 | Science | pmid:10968780 |
Wickelgren I | Mining the genome for drugs. | 1999 | Science | pmid:10475849 |
Warren JT et al. | Manipulation of receptor oligomerization as a strategy to inhibit signaling by TNF superfamily members. | 2014 | Sci Signal | pmid:25140055 |
Zang L et al. | The effects of lung and prostate cancer bone metastasis on serum osteoprotegerin levels: a meta-analysis. | 2015 | Sci Rep | pmid:26671549 |
Schiro A et al. | Elevated levels of endothelial-derived microparticles, and serum CXCL9 and SCGF-β are associated with unstable asymptomatic carotid plaques. | 2015 | Sci Rep | pmid:26564003 |
Mizuno M et al. | Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease. | 2015 | Sci Rep | pmid:26561427 |
Nemeth ZK et al. | Serum osteoprotegerin is associated with pulse pressure in kidney transplant recipients. | 2015 | Sci Rep | pmid:26459001 |
Wang B et al. | Chondrocytes-Specific Expression of Osteoprotegerin Modulates Osteoclast Formation in Metaphyseal Bone. | 2015 | Sci Rep | pmid:26329493 |
Kao SY and Stankovic KM | Transactivation of human osteoprotegerin promoter by GATA-3. | 2015 | Sci Rep | pmid:26216189 |
Hope S et al. | Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. | 2013 | Schizophr. Res. | pmid:23403415 |
Dieset I et al. | Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein. | 2012 | Schizophr. Res. | pmid:22817875 |
Gehrke T et al. | Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening. | 2003 | Scand. J. Rheumatol. | pmid:14690142 |
Spelling P et al. | Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker? | 2008 Nov-Dec | Scand. J. Rheumatol. | pmid:18802807 |
Sennels H et al. | Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate. | 2008 Jul-Aug | Scand. J. Rheumatol. | pmid:18612923 |
Feuerherm AJ et al. | Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. | 2001 | Scand. J. Rheumatol. | pmid:11578019 |
Reenaers C et al. | Sensitivity of intestinal fibroblasts to TNF-related apoptosis-inducing ligand-mediated apoptosis in Crohn's disease. | 2008 | Scand. J. Gastroenterol. | pmid:18942021 |
Yilmaz Y et al. | Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. | 2010 | Scand. J. Clin. Lab. Invest. | pmid:20942739 |
Grauslund J et al. | Does osteoprotegerin relate to micro- and macrovascular complications in long-term type 1 diabetes? | 2010 | Scand. J. Clin. Lab. Invest. | pmid:20205614 |
Bjerre M et al. | Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: the CLARICOR trial. | 2014 | Scand. J. Clin. Lab. Invest. | pmid:25026506 |
Sennels HP et al. | Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein. | 2007 | Scand. J. Clin. Lab. Invest. | pmid:17852826 |
Knudsen ST et al. | Plasma concentrations of osteoprotegerin during normo- and hyperglycaemic clamping. | 2007 | Scand. J. Clin. Lab. Invest. | pmid:17365993 |
Altinova AE et al. | Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes. | 2011 | Scand. J. Clin. Lab. Invest. | pmid:21486111 |
Muñoz-Calvo MT et al. | Maintained malnutrition produces a progressive decrease in (OPG)/RANKL ratio and leptin levels in patients with anorexia nervosa. | 2007 | Scand. J. Clin. Lab. Invest. | pmid:17558893 |
Hosbond SE et al. | Osteoprotegerin as a marker of atherosclerosis: a systematic update. | 2012 | Scand. Cardiovasc. J. | pmid:22506827 |
Stenman UH et al. | Prognostic value of serum markers for prostate cancer. | 2005 | Scand J Urol Nephrol Suppl | pmid:16019759 |
Mohamed GB and Abdel-Latif EA | Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome. | 2011 | Saudi J Kidney Dis Transpl | pmid:21912025 |
Takayanagi H | [Crosstalk between the immune and skeletal system]. | 2003 | Ryumachi | pmid:14598653 |
Gurban CV and Mederle O | The OPG/RANKL system and zinc ions are promoters of bone remodeling by osteoblast proliferation in postmenopausal osteoporosis. | 2011 | Rom J Morphol Embryol | pmid:22119834 |
Grigorie D et al. | Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. | 2003 | Rom J Intern Med | pmid:15526523 |
Grzegorzewska AE and MÅ‚ot M | Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15631341 |
Grzegorzewska AE and MÅ‚ot M | Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15631342 |
Naumnik W et al. | Serum levels of osteoprotegerin (OPG) and pro gastrin releasing peptide (ProGRP) during chemotherapy of lung cancer. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15638385 |
Fukagawa M et al. | [PTH and bone metabolism in chronic dialysis patients]. | 2001 | Rinsho Byori | pmid:11307321 |
Haynes DR et al. | Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. | 2001 | Rheumatology (Oxford) | pmid:11426018 |
Kim HR et al. | Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). | 2006 | Rheumatology (Oxford) | pmid:16567356 |
Corallini F et al. | The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis. | 2009 | Rheumatology (Oxford) | pmid:19168833 |
Smith MD | Comment on review on T cells in bone biology. | 2004 | Rheumatology (Oxford) | pmid:15448222 |
Pettit AR et al. | RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. | 2006 | Rheumatology (Oxford) | pmid:16490750 |
Bezerra MC et al. | Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis. | 2005 | Rheumatology (Oxford) | pmid:16219645 |
Kwan Tat S et al. | Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. | 2009 | Rheumatology (Oxford) | pmid:19762475 |
Castellino G et al. | The tumour necrosis factor-related apoptosis-inducing ligand-osteoprotegerin system in limited systemic sclerosis: a new disease marker? | 2010 | Rheumatology (Oxford) | pmid:20299382 |
Varsani H et al. | Synovial dendritic cells in juvenile idiopathic arthritis (JIA) express receptor activator of NF-kappaB (RANK). | 2003 | Rheumatology (Oxford) | pmid:12649407 |
Engvall IL et al. | Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I degradation by matrix metalloproteinases as assessed by serum 1CTP--a possible mechanism for specific inhibition of radiological destruction. | 2013 | Rheumatology (Oxford) | pmid:23275387 |
Huang CH et al. | Osteoprotegerin genetic polymorphisms and age of symptom onset in ankylosing spondylitis. | 2011 | Rheumatology (Oxford) | pmid:20974615 |
Hofbauer LC et al. | Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. | 2006 | Rheumatology (Oxford) | pmid:16574701 |
Breland UM et al. | Inflammatory markers in patients with coronary artery disease with and without inflammatory rheumatic disease. | 2010 | Rheumatology (Oxford) | pmid:20231178 |
Haynes DR et al. | Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. | 2003 | Rheumatology (Oxford) | pmid:12509625 |
Harashima SI et al. | Osteoprotegerin and receptor activator of nuclear factor kappaB ligand expression in fibroblast-like synoviocytes from rheumatoid arthritis and osteoarthritis patients. | 2004 | Rheumatology (Oxford) | pmid:14963213 |